Navigation Links
Hard To Treat Diseases (HTDS) Closes Acquisition of Mellow Hope, China

BEIJING, Feb. 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) is pleased to announce that it has closed the merger agreement with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope). The acquisition has been structured through a Belize based corporation; HTDS Enterprises, Inc., which is the parent company of Mellow Hope. The acquisition is valued at $8.75 million USD on an all-stock basis. The company will issue 3.5 billion restricted shares valued at 0.0025 to Mellow Hope. This will bring the outstanding share structure to 4.75 billion shares.

The merger was announced in a formal televised ceremony on Monday, February 16th. A sampling of television and press coverage can be viewed at the following websites;

    -   Television:
    -   Shanghai Security Daily and China Security Daily Report:
    -   Hong Kong and China Phoenix TV report:
    -   China investment Daily report:
    -   China's largest internet portal: 'Sohu report':
    -   China largest finance portal '':

The agreement will see Mellow Hope join Slavica Bio Chem as an active operating division of HTDS. Located in Serbia, Slavica's primary focus involves the enhancement and modification of existing approved drugs to achieve chemical repair of damage to the CNS (central nervous system) by diseases like MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.

Mellow Hope is the biggest exporter of Biological Vaccines in China, and has a product line that encompasses vaccines for hepatitis A Vaccine, Group A,C,Y,W135 meningococcal polysaccharide vaccine, influenza, tetanus, diphtheria and other diseases; cerebroprotein hydrolysate for injection and active pharmaceutical ingredient (or APIs).

Mellow Hope's Hepatitis A Vaccine (sold under the brand name MEVAC-A) will enter the Thailand market for the first time this March. Additionally, the vaccine was recently certified in Russia, and will be marketed there beginning this May. In total, the Company is in the process of registration and clinical trials in more than 20 countries in Southeast Asia, Latin America and East Europe.

Plans for growth also include building of a larger cold warehouse, developing new vaccines, such as HPV and the establishment of new offices in Yunnan, Wuhan, Kunming as well as India, and the Philippines.

Mellow Hope revenues are currently in excess of $15 million USD.

HTDS CEO, Shimin (Terry) Yuan, commented; "With the full resources of a publicly traded company, and medical experts and management in place on two continents, there will be many opportunities to create synergies between the companies. Despite issues related to the global economic slowdown, there are very many Companies in China such as Mellow Hope that will continue to expand and grow at a rapid pace."

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For scientific dialogue and inquiry only, contact Andrea Zecevic via e-mail at; For any corporate matters, readers should contact the company directly at

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Advances May Treat Stroke Faster, Better
2. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
3. High Achieving Los Angeles Charter School to Hold Health Fair Offering Free Medical Screening, Treatment and Information to Students and Their Families
4. SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment
5. New therapy with stem cells to treat Crohns disease
6. Landmark Trial Provides Vital Information for Cardiac Disease Treatment
7. Research increases possibilities of personalizing treatment of infant osteosarcoma
8. Renaissance Laser & Vein Institute ( Provides Top Notch Varicose Vein Treatment
9. Public Cancer Center Becomes First in South-East Asia to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
10. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
11. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion ... tool designed specially for Final Cut Pro X. FCPX users can ... easy-to-use modification controls. Destoying and creating chaotic distortion is now quick and simple, ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on a couch can actually ... conceived of this design due to personal experience with a bad back," he said. ... and convenience, as well as increases support. It also makes it easier to eat, ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I ... an inventor from Hillside, N.J. "Many people catch diseases simply from sitting on ... will always be protected from germs." , He developed the patent-pending QUDRATECS to ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... ) has ... Market by Type (Reagents & Kits, Analyzers), ... Diagnostic Labs), Application (Research, Clinical Diagnostics), and ... report to their offering. --> ... the "Radioimmunoassay Market by Type (Reagents ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: